cardiac remodeling, cardiomyopathy, diabetes, fatty acids, hypertension, inflammation
Digital Object Identifier (DOI)
Diabetic cardiomyopathy (DCM) or diabetes-induced cardiac dysfunction is a direct consequence of uncontrolled metabolic syndrome and is widespread in US population and worldwide. Despite of the heterogeneous and distinct features of DCM, the clinical relevance of DCM is now becoming established. DCM progresses to pathological cardiac remodeling with the higher risk of heart attack and subsequent heart failure in diabetic patients. In this review, we emphasize lipid substrate quality and the phenotypic, metabolic, and biochemical stressors of DCM in the rodent and human pathophysiology. We discuss lipoxygenase signaling in the inflammatory pathway with multiple contributing and confounding factors leading to DCM. Additionally, emerging biochemical pathways are emphasized to make progress toward therapeutic advancement to treat DCM.
This work is licensed under a Creative Commons Attribution 4.0 License.
Was this content written or created while at USF?
Citation / Publisher Attribution
Frontiers in Cardiovascular Medicine, v. 4, art. 31
Scholar Commons Citation
Kain, Vasundhara and Halade, Ganesh V., "Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy" (2017). Internal Medicine Faculty Publications. 35.